Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
Artelo Biosciences will present its experimental pain treatment ART26.12 at a major medical conference as the company advances clinical testing.· summarised by Stockedin
ARTL